Alternative dry eye disease treatment effective

Article

Sodium hyaluronate (SH) and carboxymethylcellulose (CMC) are safe and effective in treating mild to moderate dry eye disease

Sodium hyaluronate (SH) and carboxymethylcellulose (CMC) are safe and effective in treating mild to moderate dry eye disease, claimed an investigation published in Cornea.

Dr Ji Hwan Lee and his team at The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea, saw a significant improvement in both SH and CMC groups after treatment.

The prospective, randomized, blind study focused on 67 mild to moderate dry eye patients. There were 32 patients in the SH group and 33 patients in the CMC group. For 8 weeks they were administered preservative-free unit dose formula eyedrops of 0.1% SH or 0.5% CMC 6 times a day. The outcome measures included tear film break-up time, adverse reactions, subjective symptoms and corneal and conjunctival staining with fluorescein. The patients were assessed 4 weeks and 8 weeks after treatment began.

Tear film break-up time, dry eye symptom score and corneal and conjunctival staining significantly improved. There was no significant difference between both groups and no adverse reactions in the follow-up period.

SH and CMC were found to be efficient in the treatment of mild to moderate dry eye disease in the form of a preservative-free artificial tear formulation.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.